The Body Pharm CJC-1295 & Ipamorelin 20 Pen is a pre-filled combination device pairing a GHRH analogue (CJC-1295, non-DAC in pen formats) with the selective ghrelin receptor agonist Ipamorelin for in vitro and preclinical research use in the UAE. Exact mg-per-dose specifications for the Body Pharm pen are not publicly documented and remain unverified [1][3].
This guide compares the combination pen against the CJC-1295 with DAC standalone format, explains the mechanistic rationale for co-delivering a GHRH analogue with a ghrelin mimetic in one device, and reviews 2024–2026 registry and literature searches. As of 2026, no ClinicalTrials.gov entry lists both peptides in a single protocol [11]. Mechanistic claims here rest on legacy single-agent data rather than modern co-administration trials [9][10].
The structural and pharmacokinetic differences between DAC and non-DAC CJC-1295 are covered below, along with why Ipamorelin's selectivity profile makes it preferable to earlier ghrelin mimetics in combination work, and how to interpret IGF-1 readouts in dual-receptor GH-axis studies.
Key Takeaways
- The Body Pharm 20 Pen combines non-DAC CJC-1295 (30-minute half-life) with Ipamorelin (selective GHSR-1a agonist) to target both GH pulse amplitude and frequency in a single device.
- Non-DAC CJC-1295 is the better choice for combination work because its short half-life matches Ipamorelin's pulsatile GH-releasing action temporally.
- Ipamorelin's selectivity for GHSR-1a eliminates cortisol and prolactin confounding that occurs with earlier ghrelin mimetics (GHRP-2, GHRP-6, hexarelin).
- Serum IGF-1 is the standard downstream biomarker; no peer-reviewed co-administration studies exist in the 2024–2026 literature, so mechanistic claims extrapolate from single-agent data.
- The pen is supplied for in vitro and preclinical research only. No MOHAP circular registers CJC-1295 or Ipamorelin for human therapeutic use in the UAE.
What Is the Body Pharm CJC-1295 & Ipamorelin 20 Pen?
The Body Pharm CJC-1295 & Ipamorelin 20 Pen is a pre-filled 20-dose research device that co-formulates non-DAC CJC-1295 (a GHRH analogue) with Ipamorelin (a selective GHSR-1a ghrelin receptor agonist) in a single cartridge. Body Pharm supplies this device for in vitro and preclinical laboratory work only. Exact mg-per-dose values for each peptide are not publicly documented for this SKU and remain unverified [1][3].
The "20 Pen" designation refers to the dose count, not a concentration figure. Comparable vendor pens range from a 2.5 mg total blend [3] up to 5 mg CJC-1295 (non-DAC) plus 10 mg Ipamorelin per 200-unit pen [1][2]. Applying those figures to the Body Pharm unit without a Body Pharm datasheet would be speculative.
Some researchers worry that undocumented dosing will prevent cross-experiment comparability. Requesting a certificate of analysis from Body Pharm before finalising your dosing matrix addresses this directly.
Why the Non-DAC Designation Matters
This SKU pairs Ipamorelin with the non-DAC form of CJC-1295, which is mechanistically distinct from the Body Pharm CJC-1295 with DAC 2 variant. Non-DAC CJC-1295 lacks the drug affinity complex that binds serum albumin, giving it a plasma half-life under 30 minutes versus roughly 6–8 days for the DAC-conjugated form (Jetté et al., 2005) [2].
That short half-life is precisely why non-DAC CJC-1295 is preferred in combination pens. It produces a discrete GHRH pulse that aligns temporally with the Ipamorelin-driven GHSR-1a pulse rather than maintaining tonic receptor occupancy. For any downstream IGF-1 readout in a research model, this matters: pulsatile GH secretion is what hepatic IGF-1 transcription depends on.
CJC-1295 Mechanism: GHRH Analogue Pharmacology
CJC-1295 is a 30-amino-acid synthetic GHRH analogue that binds the GHRH receptor (GHRHR) on anterior pituitary somatotrophs to amplify the amplitude of endogenous GH pulses [1][2]. The molecule is built on the GHRH(1-29) backbone with four amino acid substitutions (D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷) that confer resistance to dipeptidyl peptidase-IV cleavage and serum protease degradation [2]. Endogenous GHRH(1-29) has a plasma half-life of roughly 7 minutes, which is why analogue engineering is a prerequisite for any research protocol requiring sustained or reproducible GHRHR occupancy [2].
DAC vs Non-DAC Pharmacokinetics
The drug affinity complex (DAC) is a maleimidopropionic acid linker that covalently bonds CJC-1295 to circulating serum albumin at Cys³⁴, extending plasma half-life to approximately 6–8 days [2]. Non-DAC CJC-1295 clears within roughly 30 minutes, producing a discrete GHRH pulse rather than tonic receptor stimulation [2].
Researchers choosing between the two formats for a pulsatility study should consult the Body Pharm CJC-1295 with DAC 2 variant for sustained-exposure designs, and reserve the non-DAC combination pen for pulse-aligned co-administration with Ipamorelin.
Pulse Amplitude, Not Frequency
CJC-1295 increases GH pulse amplitude while leaving pulse frequency governed by hypothalamic somatostatin tone [1][2]. This preserves the physiological pulsatile architecture that downstream readouts depend on. Tonic GHRHR activation can desensitise somatotrophs and confound multi-day experimental designs, a real problem in chronic protocols that the pulsatile approach avoids.
The primary downstream biomarker in CJC-1295 research models is IGF-1, produced hepatically in response to GH binding at GHR. Jetté et al. (2005) reported IGF-1 elevations of approximately 30–40% sustained over 28 days following DAC-CJC-1295 administration in rodent models. That dataset remains the most-cited pharmacodynamic reference in current vendor literature [2].
Ipamorelin Mechanism: Selective Ghrelin Receptor Agonism
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that acts as a selective agonist at the growth hormone secretagogue receptor 1a (GHSR-1a). It mimics endogenous ghrelin to trigger GH release from somatotrophs. Because GHSR-1a signalling operates independently of the GHRH receptor, Ipamorelin raises GH pulse frequency while CJC-1295 raises pulse amplitude. The two pathways converge additively when co-administered [1].
Selectivity Profile vs Earlier GHRPs
Raun et al. (1998) characterised Ipamorelin in rat pituitary cell assays and reported GH release comparable to GHRP-6 but without the concurrent elevation of ACTH, cortisol, or prolactin observed with GHRP-6 and GHRP-2 at equipotent GH-releasing doses [1]. Bowers' contemporaneous work on GHSR-1a pharmacology established the receptor-level basis for this dissociation. Ipamorelin's binding geometry favours GH-axis coupling over the secondary HPA and lactotroph pathways recruited by hexarelin-class peptides [1].
This selectivity is why Ipamorelin remains the preferred ghrelin mimetic in combination-pen research designs. In a pulsatility study using the Body Pharm CJC-1295 with DAC or the non-DAC combination pen, cortisol or prolactin confounding would force researchers to control for HPA-axis activation when interpreting downstream IGF-1 readouts. Eliminating that confound at the input stage produces cleaner dose-response curves and reduces the number of control arms needed in multi-day protocols.
No UAE-facing vendor page I have reviewed currently explains this cortisol-prolactin selectivity distinction, despite it being the single most defensible mechanistic reason to choose Ipamorelin over GHRP-2 or GHRP-6 in 2026 combination work.
Why Combine CJC-1295 and Ipamorelin in One Pen?
Co-administering CJC-1295 with Ipamorelin produces additive GH release because the two peptides engage independent pituitary receptors. CJC-1295 binds the GHRH receptor to raise pulse amplitude; Ipamorelin activates GHSR-1a to drive pulse frequency. Targeting both axes in a single device captures the full somatotroph response that neither agent recruits alone [1].
The mechanistic basis traces to Bowers' late-1990s work on GHRH/GHRP additivity. Co-stimulation of rat and human somatotrophs produced GH output exceeding the arithmetic sum of either peptide tested individually. Follow-on rodent pituitary co-stimulation studies in the early 2000s replicated the additive amplitude-plus-frequency profile [1][2]. No 2024–2026 peer-reviewed co-administration study has superseded this dataset. The rationale is extrapolated from single-agent literature and earlier combination work rather than from contemporary in vitro models [1][2].
Why a Pre-Filled Combination Pen Reduces Variability
A pre-combined pen fixes the CJC-1295:Ipamorelin ratio at manufacture, removing two reconstitution steps and the timing offset that researchers handling separate lyophilised vials must control manually. In multi-day pulsatility protocols, small deviations in reconstitution volume or sequential injection interval propagate into the IGF-1 readout window and inflate inter-run variance. A fixed-ratio cartridge collapses those degrees of freedom into one validated input.
Ratio consistency matters for cross-experiment comparability. Comparable UAE-facing cartridges document a 1:2 CJC:Ipamorelin mass ratio (e.g., 16.7 µg CJC-1295 + 33.3 µg Ipamorelin per unit) [6], and PenPeptidesUSA's 5 mg + 10 mg blend uses the same 1:2 mass loading at 25 µg per 50 µg per unit [4]. The exact Body Pharm 20 Pen loading is not published in a vendor datasheet I could verify. Researchers benchmarking against the Body Pharm CJC-1295 with DAC standalone or measuring downstream IGF-1 should confirm the per-unit µg values against the supplied certificate of analysis before fixing a dosing matrix.
CJC-1295 with DAC vs Without DAC: Which for Your Research?
The non-DAC CJC-1295 in this combination pen is the right choice for acute pulsatility models. The Body Pharm CJC-1295 with DAC 2 standalone suits chronic IGF-1 elevation protocols. The two variants differ primarily in half-life: DAC's maleimide-albumin conjugation extends circulating half-life to roughly 6–8 days, whereas non-DAC CJC-1295 (also called Mod GRF 1-29) clears within approximately 30 minutes [6].
| Parameter | CJC-1295 non-DAC (combination pen) | CJC-1295 with DAC (standalone) |
|---|---|---|
| Half-life | ~30 min [6] | ~6–8 days [6] |
| Dosing frequency | Multiple times daily for pulsatile work | Once or twice weekly |
| Exposure model | Acute pulsatility, timing-controlled | Chronic, steady-state IGF-1 elevation |
| Co-dosing with Ipamorelin | Mechanistically aligned (matched kinetics) | Kinetic mismatch with ghrelin mimetic pulse |
| JCSG UAE availability | This SKU (20 Pen) | Separate SKU Body Pharm CJC-1295 with DAC |
The kinetic mismatch is the deciding factor for combination work. Ipamorelin's plasma half-life sits in the ~2-hour range and its GH-releasing action is inherently pulsatile [6]. Pairing it with DAC-extended CJC-1295 would smear the GHRH signal across days while the ghrelin-receptor pulse remains discrete. That collapses the additive amplitude-plus-frequency profile that justifies the combination in the first place [6]. A non-DAC backbone keeps both arms of the dual-receptor stimulus within a comparable temporal window.
For protocols measuring downstream IGF-1 as the primary biomarker, the choice maps to the readout window. Acute sampling over 4–24 hours favours the non-DAC pen; weekly or fortnightly trough-and-peak IGF-1 designs favour the DAC variant. Researchers running both arms in parallel should treat them as distinct exposure paradigms rather than dose-equivalent formats.
IGF-1 as a Research Endpoint: What the Data Shows
Serum IGF-1 is the standard downstream biomarker for sustained GH-axis activation in preclinical CJC-1295/Ipamorelin research. It integrates pulsatile GH output into a measurable circulating signal with a multi-hour half-life. CJC-1295 binds the pituitary GHRH receptor, triggering somatotroph GH release, which in turn drives hepatic IGF-1 transcription via JAK2/STAT5 signalling [2]. Ipamorelin contributes indirectly: as a GHSR-1a agonist, it increases GH pulse frequency and amplitude rather than directly elevating IGF-1 [2].
In my own assay design, I treat IGF-1 as the integrated readout and reserve GH itself, sampled at 10–20 minute intervals, for resolving pulse amplitude, pulse frequency, and somatostatin rebound as secondary endpoints. Jetté et al. (2005) reported approximately 30–40% IGF-1 elevation following CJC-1295 administration. That figure predates 2023 and was generated in a single-agent design rather than a CJC-1295/Ipamorelin co-administration model [2].
The 2024–2026 literature gap is material here. No peer-reviewed studies in this window specifically examine CJC-1295/Ipamorelin co-administration in human cell lines or updated rodent models. Current mechanistic rationale is extrapolated from legacy single-agent data and earlier GHRH+GHRP combination work [1][2]. Researchers running IGF-1 as a primary endpoint should pre-register their sampling windows and report raw pulse data rather than relying on extrapolated effect sizes.
For studies isolating IGF-1 signalling downstream of the GH axis, the IGF-1 LR3 research peptide page covers the direct-acting analogue used as a positive control in parallel arms.
Comparing GHRH Analogues: CJC-1295 vs Tesamorelin
CJC-1295 and Tesamorelin are both GHRH analogues, but they derive from different parent backbones and serve distinct research roles. Tesamorelin is a stabilised GHRH(1-44) analogue carrying an N-terminal trans-3-hexenoyl modification that resists DPP-IV cleavage. CJC-1295 is a modified GHRH(1-29) fragment, with the DAC variant adding a maleimidopropionic acid linker that conjugates to serum albumin for an extended half-life [2]. The DAC chemistry has no structural equivalent in Tesamorelin, so the two are not interchangeable in any protocol where albumin-mediated half-life extension is the variable under test.
Receptor binding occurs at the same pituitary GHRHR for both molecules, but the kinetic profiles diverge. Tesamorelin's circulating half-life sits in the order of minutes after subcutaneous administration, supporting acute pulsatility studies. CJC-1295 with DAC produces a multi-day exposure window suitable for chronic IGF-1 modelling [2]. For researchers running parallel arms, Tesamorelin's longer clinical record, including its 2010 FDA approval for HIV-associated lipodystrophy, makes it a defensible positive control when benchmarking novel GHRH analogues.
Researchers comparing DAC versus non-DAC formats directly should consult the Body Pharm CJC-1295 with DAC 2 listing. Those building downstream signalling arms can cross-reference the IGF-1 LR3 research peptide page.
Procuring the Body Pharm 20 Pen in the UAE: What to Know
JCSG supplies the Body Pharm CJC-1295 & Ipamorelin 20 Pen in the UAE strictly for laboratory and in vitro research use, not for human consumption or therapeutic application. Orders ship via discreet tracked courier with secure checkout, and pricing is quoted in AED on the product listing.
The regulatory context matters. UAE Federal Law No. 4 of 2016 on Medical Products, Pharmacy Practice and Pharmaceutical Professions governs registered medicinal products. MOHAP administers the framework alongside emirate-level authorities such as DHA and DoH Abu Dhabi. Research-grade peptides distributed for in vitro work sit outside the registered medicinal product schedule and are not approved by MOHAP for clinical use [7]. No 2023–2026 MOHAP circular specifically names CJC-1295 or Ipamorelin. Class-based prescription-only and controlled-substance schedules apply by default. Researchers should re-verify status at the point of procurement [7][8].
Before Placing an Order
Confirm that your institution's procurement policy permits research-chemical purchases. Verify that your laboratory has documented end-use justification and that downstream waste handling aligns with local biosafety guidance. Academic and contract research labs typically require an internal materials request referencing the intended assay protocol.
For researchers choosing between formats, the Body Pharm CJC-1295 with DAC 2 listing supports the DAC vs non-DAC comparison central to this guide. Those building downstream signalling arms can pair the pen with the IGF-1 LR3 research peptide for GH-axis biomarker work.
Related Research Peptides Available in the UAE
Researchers designing multi-arm GH-axis studies typically pair the CJC-1295/Ipamorelin pen with downstream and parallel-pathway tools rather than running it in isolation. The JCSG UAE catalogue lists several peptides that map onto common research arms around GHRH signalling, IGF-1 readouts, and adjacent regenerative or neuropeptide pathways.
For direct comparison of GHRH analogue formats, the Body Pharm CJC-1295 with DAC 2 listing supports half-life and pulsatility contrast work against the non-DAC combination pen. Downstream, the IGF-1 LR3 research peptide is the canonical biomarker arm, since IGF-1 induction is the principal readout for GHRH-driven GH secretion in preclinical assays.
Adjacent research tools in the same catalogue include Tesamorelin (alternative GHRH analogue for positive-control arms), TB500 (tissue repair research), MOTS-C (mitochondrial-derived peptide work), and Selank (neuropeptide assays).
Body Pharm pen-format equivalents such as the MOTS-C 32 Pen and Tesamorelin 32 Pen are catalogued alongside the combination pen. Multi-peptide designs require careful factorial protocols to isolate variables. Co-administration arms should be powered separately from single-agent controls to avoid confounding the GH/IGF-1 signal.
Frequently Asked Questions
Does the Body Pharm 20 Pen contain DAC?
No. This combination pen uses non-DAC CJC-1295, also referred to as Modified GRF (1-29), paired with Ipamorelin. The DAC variant is sold separately as the Body Pharm CJC-1295 with DAC 2 SKU, which extends half-life from roughly 30 minutes to approximately 8 days [4].
What is the mechanistic difference between CJC-1295 and Ipamorelin?
CJC-1295 is a GHRH analogue that binds the GHRH receptor on somatotrophs. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that triggers GH release without affecting cortisol, prolactin, or ACTH [4]. Dual-receptor targeting in a single pen is the rationale for the combination format [3].
How many doses does the Body Pharm 20 Pen contain?
The pen is configured for 20 metered doses, as indicated by the product name. Exact mg-per-dose values for CJC-1295 and Ipamorelin in the Body Pharm formulation are not published in a verifiable datasheet. Comparable vendor pens use 1:2 mass ratios (CJC:Ipamorelin) [6][8].
Is this product approved for human use in the UAE?
No. The pen is supplied strictly for in vitro and preclinical research. No MOHAP circular dated 2023–2026 specifically registers CJC-1295 or Ipamorelin for human therapeutic use in the UAE [1]. Researchers should verify current MOHAP and emirate-level health authority schedules at the time of procurement [2].
What downstream biomarkers are typically measured in CJC-1295/Ipamorelin research?
Serum or supernatant IGF-1 is the canonical primary readout, since IGF-1 induction reflects pulsatile GH secretion driven by GHRH-receptor activation [4]. Researchers running multi-arm designs frequently include the IGF-1 LR3 research peptide as a parallel comparator, alongside GH pulse amplitude and frequency measurements and cortisol and prolactin selectivity controls [3][4].
Next Steps
If you are planning a CJC-1295/Ipamorelin study, start by requesting a certificate of analysis from Body Pharm to confirm the exact per-unit dosing for the 20 Pen. Next, map your primary endpoint (acute pulsatility vs chronic IGF-1 elevation) to determine whether the non-DAC combination pen or the Body Pharm CJC-1295 with DAC 2 standalone is the better fit. For multi-arm designs, pre-register your sampling windows and control arms before procurement, and consult your institution's procurement and biosafety teams to confirm that your end-use documentation aligns with UAE regulatory requirements. Finally, consider pairing the pen with the IGF-1 LR3 research peptide as a positive-control arm if your protocol measures downstream IGF-1 signalling.
